Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takehiro Takahashi

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
The Journal of Dermatology|May 13, 2014
Successful use of intravenous cyclophosphamide pulse therapy for interstitial lung disease in a patient with systemic sclerosis on hemodialysisTakehiro Takahashi, Yoshihide Asano, Ryo Sunaga, et al.
The Journal of Dermatology|May 1, 2016
Linear scleroderma with prominent multiple lymphadenopathy followed by the development of polymyositis: A case report and review of published workTakehiro Takahashi, Yoshihide Asano, Maiko Hirakawa, et al.
Experimental Dermatology|June 28, 2018
CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosisTakashi Taniguchi, Takuya Miyagawa, Satoshi Toyama, et al.
The Journal of Dermatology|February 16, 2016
Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosisRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 8, 2014
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine modelsSeiji Okazaki, Takehiro Takahashi, Tomokatsu Iwamura, et al.
Modern Rheumatology|August 20, 2016
Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung diseaseRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
Nature Microbiology|March 13, 2019
Aedes aegypti AgBR1 antibodies modulate early Zika virus infection of miceRyuta Uraki, Andrew K Hastings, Alejandro Marin-Lopez, et al.
Clinical Pharmacology and Therapeutics|February 9, 2020
Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer PatientsYutaro Kubota, Ken-Ichi Fujita, Takehiro Takahashi, et al.
The Journal of Investigative Dermatology|May 23, 2017
Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 DeficiencyRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2018
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancerHideaki Bando, Hideki Shimodaira, Kazumasa Fujitani, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
The Journal of Dermatology|May 13, 2014
Successful use of intravenous cyclophosphamide pulse therapy for interstitial lung disease in a patient with systemic sclerosis on hemodialysisTakehiro Takahashi, Yoshihide Asano, Ryo Sunaga, et al.
The Journal of Dermatology|May 1, 2016
Linear scleroderma with prominent multiple lymphadenopathy followed by the development of polymyositis: A case report and review of published workTakehiro Takahashi, Yoshihide Asano, Maiko Hirakawa, et al.
Experimental Dermatology|June 28, 2018
CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosisTakashi Taniguchi, Takuya Miyagawa, Satoshi Toyama, et al.
The Journal of Dermatology|February 16, 2016
Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosisRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 8, 2014
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine modelsSeiji Okazaki, Takehiro Takahashi, Tomokatsu Iwamura, et al.
Modern Rheumatology|August 20, 2016
Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung diseaseRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
Nature Microbiology|March 13, 2019
Aedes aegypti AgBR1 antibodies modulate early Zika virus infection of miceRyuta Uraki, Andrew K Hastings, Alejandro Marin-Lopez, et al.
Clinical Pharmacology and Therapeutics|February 9, 2020
Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer PatientsYutaro Kubota, Ken-Ichi Fujita, Takehiro Takahashi, et al.
The Journal of Investigative Dermatology|May 23, 2017
Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 DeficiencyRyosuke Saigusa, Yoshihide Asano, Kouki Nakamura, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2018
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancerHideaki Bando, Hideki Shimodaira, Kazumasa Fujitani, et al.
Pageof 14